Provided by Tiger Fintech (Singapore) Pte. Ltd.

Vor Biopharma Inc.

25.00
-0.5000-1.96%
Post-market: 25.220.2188+0.88%19:56 EDT
Volume:204.05K
Turnover:5.09M
Market Cap:171.35M
PE:-0.07
High:25.56
Open:25.16
Low:24.59
Close:25.50
52wk High:65.80
52wk Low:2.62
Shares:6.85M
Float Shares:3.18M
Volume Ratio:0.45
T/O Rate:6.43%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-342.6591
EPS(LYR):-34.0333
ROE:-125.43%
ROA:-121.29%
PB:-0.11
PE(LYR):-0.73

Loading ...

Vor Biopharma Announces Positive Phase 3 Trial Results for Telitacicept in Lupus, Published in NEJM

Reuters
·
Oct 16

Major Stakeholder Sells Big on Vor Biopharma!

TIPRANKS
·
Oct 16

Reprogrammed Interchange LLC Reports Disposal of Common Shares of Vor Biopharma Inc

Reuters
·
Oct 16

Vor Biopharma Raised to Outperform From Neutral by Baird

Dow Jones
·
Oct 15

U.S. RESEARCH ROUNDUP- BlackRock, EQT, Ovintiv

Reuters
·
Oct 15

Vor Biopharma Inc : Baird Raises to Outperform Rating; Raises Target Price to $64 From $20

THOMSON REUTERS
·
Oct 15

Vor Bio upgraded to Outperform from Neutral at Baird

TIPRANKS
·
Oct 15

Vor Biopharma Announces Positive Phase 3 Results for Telitacicept in Primary Sjögren’s Disease, Plans Global Study

Reuters
·
Oct 14

Telitacicept Demonstrates Clinically Meaningful and Statistically Significant Impact on Essdai Compared to Placebo in Late-Breaking China Phase 3 Results in Primary SjÖGren’s Disease at Acr 2025

THOMSON REUTERS
·
Oct 14

Vor Biopharma Inc - Study Meets Primary and Secondary Endpoints With Telitacicept

THOMSON REUTERS
·
Oct 14

Vor Biopharma Inc - Telitacicept Shows Favorable Safety Profile Comparable to Placebo

THOMSON REUTERS
·
Oct 14

Vor Biopharma Inc - Telitacicept Shows Favorable Safety Profile

THOMSON REUTERS
·
Oct 14

Vor Biopharma Inc.'s (NASDAQ:VOR) Intrinsic Value Is Potentially 55% Above Its Share Price

Simply Wall St.
·
Oct 11

Major Shareholder Sells Massive Stake in Vor Biopharma!

TIPRANKS
·
Oct 09

Reprogrammed Interchange LLC Reports Disposal of Common Shares of Vor Biopharma Inc

Reuters
·
Oct 09

Reprogrammed Interchange LLC Reports Disposal of Common Shares in Vor Biopharma Inc

Reuters
·
Oct 04

BRIEF-Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule

Reuters
·
Oct 04

Vor Biopharma Announces Positive Phase 3 Clinical Trial Results for Telitacicept in Primary Sjögren’s Disease; Data to Be Presented at ACR Convergence 2025

Reuters
·
Sep 29

Verve Capital Limited Reports 9.9% Passive Stake in Vor Biopharma Inc as of Sept 18 - SEC Filing

THOMSON REUTERS
·
Sep 26

BRIEF-Vor Biopharma Files For Offering Of Up To 51 Million Common Shares By The Selling Stockholders - SEC Filing

Reuters
·
Sep 25